Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
NPJ Precision Oncology
|
May 6, 2024
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
NPJ Precision Oncology
|
April 8, 2024
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumors
Ian M Silverman, Joseph D Schonoft, Benjamin Herzberg, et al.
British Journal of Cancer
|
February 24, 2022
Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential
Mar Giner-Calabuig, Seila De Leon, Julian Wang, et al.
JCO Clinical Cancer Informatics
|
January 9, 2026
Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials
Guannan Gong, Jessica Liu, Sameer Pandya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
The Oncologist
|
July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
Gregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
NPJ Precision Oncology
|
May 6, 2024
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
NPJ Precision Oncology
|
April 8, 2024
Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Aurel Prosz, Pranshu Sahgal, Brandon M Huffman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumors
Ian M Silverman, Joseph D Schonoft, Benjamin Herzberg, et al.
British Journal of Cancer
|
February 24, 2022
Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential
Mar Giner-Calabuig, Seila De Leon, Julian Wang, et al.
JCO Clinical Cancer Informatics
|
January 9, 2026
Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence-Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials
Guannan Gong, Jessica Liu, Sameer Pandya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2026
Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
Manish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Cancer
|
February 7, 2025
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, et al.
The Oncologist
|
July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
Gregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
Page
of 7